INT110258

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.56
First Reported 2003
Last Reported 2011
Negated 0
Speculated 0
Reported most in Body
Documents 6
Total Number 6
Disease Relevance 5.42
Pain Relevance 0.39

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

Golgi apparatus (PTHLH) intracellular (PTHLH) cell-cell signaling (PTHLH)
cytoplasm (PTHLH) extracellular space (PTHLH) extracellular region (PTHLH)
PTHLH (Homo sapiens)
Pain Link Frequency Relevance Heat
Somatostatin 2 99.72 Very High Very High Very High
Inflammation 7 70.80 Quite High
cytokine 6 70.60 Quite High
palliative 3 60.96 Quite High
fibrosis 110 46.44 Quite Low
adenocard 2 45.04 Quite Low
antagonist 2 42.80 Quite Low
Catecholamine 9 23.88 Low Low
Dopamine 8 5.00 Very Low Very Low Very Low
Pain 4 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Malignant Neoplastic Disease 11 100.00 Very High Very High Very High
Cancer 10 98.84 Very High Very High Very High
Hypercalcemia 48 97.80 Very High Very High Very High
Adult T-cell Leukemia-lymphoma 34 96.16 Very High Very High Very High
Cognitive Disorder 2 96.04 Very High Very High Very High
Fatigue 2 95.12 Very High Very High Very High
Dyspnea 1 94.76 High High
Vomiting 6 94.36 High High
Appetite Loss 6 93.56 High High
Osteoporosis 14 91.68 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
However, there are case reports of the successful use of somatostatin analogues in reducing PTHrP and calcium levels in other tumours[9,10].
Negative_regulation (reducing) of PTHrP associated with cancer and somatostatin
1) Confidence 0.56 Published 2007 Journal J Med Case Reports Section Body Doc Link PMC1950877 Disease Relevance 1.48 Pain Relevance 0.15
Recently, a monoclonal antibody against PTHrP has been shown to block PTHrP function and reduce calcium levels in mouse models of hypercalcaemia[11].
Negative_regulation (block) of PTHrP associated with hypercalcemia
2) Confidence 0.41 Published 2007 Journal J Med Case Reports Section Body Doc Link PMC1950877 Disease Relevance 1.37 Pain Relevance 0.14
These five include known inhibitors (quercetin, DBHD, PLP, and PCP), as well as isoprenaline, which binds to SULT1B1 only in the absence of PAP and is a poor substrate for this enzyme (Tables 1 and 2).
Negative_regulation (inhibitors) of PLP
3) Confidence 0.23 Published 2007 Journal PLoS Biology Section Body Doc Link PMC1847840 Disease Relevance 0.14 Pain Relevance 0.04
Unlike PTH, which has both anabolic and catabolic effects on bone, PTHrP appears to be purely anabolic when administered intermittently.
Negative_regulation (anabolic) of PTHrP
4) Confidence 0.16 Published 2011 Journal Journal of Osteoporosis Section Body Doc Link PMC3010683 Disease Relevance 0.24 Pain Relevance 0
Pregnant rats were exposed to vehicle or low doses of BDE-47 (2, 20 and 200 ?
Negative_regulation (doses) of BDE-47
5) Confidence 0.09 Published 2008 Journal Environ Health Section Body Doc Link PMC2596097 Disease Relevance 0.14 Pain Relevance 0
The patients with HHM who were administrated drugs such as bisphosphonate and calcitonin showed a reduction in their Ca and PTH-rP levels, and the six of ten EORTC QLQ-C30 subscales (emotional functioning, cognitive functioning, fatigue, dyspnoea, nausea/vomiting and appetite loss) were also improved after the anti-hypercalcemic therapy.
Negative_regulation (reduction) of HHM associated with appetite loss, cognitive disorder, malignant neoplastic disease, vomiting, fatigue and dyspnea
6) Confidence 0.06 Published 2003 Journal Int J Oral Maxillofac Surg Section Abstract Doc Link 12729778 Disease Relevance 2.04 Pain Relevance 0.06

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox